JSF Financial’s Definium Therapeutics DFTX Stock Holding History

JSF Financial’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,214	Closed	-$20K	–	112
2022 Q1	$20K	Buy	+1,214	New	+$21.1K	0.01%	112

Other funds holding DFTX

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JSF Financial's DFTX Position: Q2 2022 in Review

JSF Financial sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 1,214 shares — an estimated $20K sold.

JSF Financial first reported a position in DFTX in Q1 2022 and held it in 1 quarter. The position peaked at $20K in Q1 2022. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

JSF Financial reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
JSF Financial sold 1,214 Definium Therapeutics shares in Q2 2022, an estimated $20K.
JSF Financial first reported a position in Definium Therapeutics in Q1 2022 and held it in 1 quarter.
JSF Financial's Definium Therapeutics position peaked at $20K in Q1 2022.
155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on JSF Financial's 13F filing for Q2 2022, filed 28 Jul 2022.